Tirzepatide Beats Semaglutide for Weight Loss—But Not for the Heart

For years, patients and clinicians have debated which GLP-1 receptor agonist delivers better outcomes: tirzepatide or semaglutide. Now we have head-to-head data, and the answer depends on what you're measuring.

Eli Lilly's SURMOUNT-5 trial, published in The New England Journal of Medicine in May 2025, gave tirzepatide the edge on weight loss. Over 72 weeks, patients on the maximum dose of tirzepatide (15 mg) lost an average of 20.2% of their body weight compared to 15.0% on semaglutide 2.4 mg. That's a 5.2 percentage point difference in favor of tirzepatide.

But real-world cardiovascular data presented at the International Stroke Conference in 2026 flipped the narrative. Semaglutide reduced the risk of major adverse cardiovascular events (MACE) by 57% more than tirzepatide in patients with obesity and cardiovascular disease who did not have diabetes. The findings come from a retrospective analysis of electronic health records, not a randomized controlled trial, but the signal is strong enough to matter in clinical decision-making.

The Weight Loss Winner

SURMOUNT-5 enrolled 751 adults with obesity or overweight and at least one weight-related comorbidity. Participants were randomized to receive either tirzepatide up to 15 mg weekly or semaglutide 2.4 mg weekly. The primary endpoint was percentage change in body weight at 72 weeks.

Tirzepatide delivered a mean weight reduction of 20.2% versus 15.0% for semaglutide. The treatment difference was statistically significant at 5.2 percentage points (95% CI: 3.8 to 6.5). More than half of tirzepatide-treated patients (54.5%) achieved at least 20% weight loss, compared to 31.4% on semaglutide.

Secondary endpoints favored tirzepatide as well. Improvements in waist circumference, blood pressure, and lipid profiles were greater in the tirzepatide arm. Adverse event rates were similar between the two drugs, with gastrointestinal side effects being the most common reason for discontinuation in both groups.

The cost-effectiveness data from an earlier economic analysis showed that the cost to treat each 1% reduction of body weight was $985 with tirzepatide and $1,845 with semaglutide, based on pricing before the TrumpRx negotiations announced in early 2026. Those figures may shift as new government-negotiated pricing takes effect, but the relative efficiency margin remains notable.

The Cardiovascular Split

The SURMOUNT-5 trial was not powered to detect cardiovascular outcomes. That's where the real-world data matters.

Researchers analyzed electronic health records from over 30,000 patients with obesity and established cardiovascular disease but without diabetes. The cohort was split between those prescribed semaglutide and those prescribed tirzepatide. Over a median follow-up period of 18 months, semaglutide was associated with a 57% greater reduction in MACE compared to tirzepatide.

MACE was defined as the composite of myocardial infarction, stroke, and cardiovascular death. The hazard ratio favoring semaglutide was 0.68 (95% CI: 0.59 to 0.79). This is consistent with the cardiovascular benefits demonstrated in the SELECT trial, which showed semaglutide reduced MACE by 20% in patients with obesity and cardiovascular disease.

Tirzepatide has its own cardiovascular outcomes trial underway—SURMOUNT-MMO—but results are not expected until late 2026 or early 2027. Until then, semaglutide holds the stronger cardiovascular evidence base, at least in patients with pre-existing heart disease.

Dual Agonism vs. Single Agonism

The mechanistic difference between the two drugs may explain the divergent outcomes. Tirzepatide is a dual GIP/GLP-1 receptor agonist. The additional GIP activity appears to enhance weight loss, possibly through increased energy expenditure and appetite suppression. Semaglutide, by contrast, is a selective GLP-1 receptor agonist with well-established cardiovascular benefits tied to improvements in endothelial function, inflammation, and atherosclerotic plaque stability.

Some researchers speculate that GIP agonism, while beneficial for metabolic outcomes, may not confer the same cardiovascular protection as isolated GLP-1 activity. But this remains speculative. The SURMOUNT-MMO trial will provide clarity.

What This Means for Prescribing

The head-to-head data creates a clinical decision tree. For patients with obesity whose primary goal is weight loss and who do not have established cardiovascular disease, tirzepatide offers a meaningful advantage. The 5.2 percentage point difference translates to an additional 11 to 13 pounds of weight loss for a 200-pound patient.

For patients with obesity and documented cardiovascular disease, the evidence favors semaglutide. The 57% greater MACE reduction is substantial, even if it comes from observational data. In this population, the cardiovascular benefit may outweigh the incremental weight loss advantage of tirzepatide.

Insurance coverage remains a wildcard. Some payers have begun restricting coverage to one agent or the other based on formulary agreements. The TrumpRx pricing deals announced in February 2026 may improve access, but implementation timelines remain unclear, and not all patients will qualify for government-negotiated pricing.

The Bigger Picture

The tirzepatide-semaglutide comparison is not a binary winner-takes-all scenario. These are both highly effective medications with different strengths. The SURMOUNT-5 data settles the weight loss question. The cardiovascular data, while observational, points to a clinically significant difference that cannot be ignored.

What remains unsettled is whether tirzepatide will demonstrate cardiovascular benefits in its dedicated outcomes trial. If SURMOUNT-MMO shows non-inferiority or superiority to standard of care, the calculus shifts again. For now, clinicians have enough evidence to make informed, individualized choices.

The regulatory and reimbursement environment is shifting fast. FDA approval of tirzepatide's multi-dose KwikPen in early 2026 improves convenience and reduces medication errors. Meanwhile, ongoing price negotiations and the introduction of compounded formulations are creating a more competitive market. Patients benefit when evidence, not marketing budgets, drives prescribing decisions.